Rüdiger Eming

TL;DR: Recommendations from a subsequent Delphi consensus to broaden the generalizability of recommendations includes intravenous CD20 inhibitors as a first line therapy option for moderate to severe pemphigus.

TL;DR: It is found that rituximab therapy can help pemphigus patients even after 6 years, in part by reshaping the B cell repertoire during reconstitution, allowing for long-term effects in addition to the short-term loss of pathogenic B cells.

TL;DR: Data from this registry indicate that rituximab is a commonly employed, well-tolerated therapy with potential beneficial effects in standard of care-refractory autoimmune diseases, and support the results from other open-label, uncontrolled studies.

TL;DR: Recently, a subset of autoreactive T cells with remarkable regulatory function was identified in healthy individuals and to a much lesser extent in patients with PV, suggesting that the occurrence of autoimmune bullous disorders may be linked to a dysfunction of Tregs.

TL;DR: A newly developed autoimmune bullous skin disorder intensity score (ABSIS) is introduced and discussed to reflect the disease activity of individual patients by a standardised scoring system.